When a Weight-Loss Medicine Meets Alcohol Use Disorder A new randomized trial of oral semaglutide found fewer heavy-drinking days and fewer alcohol-related consequences—but missed its primary craving outcome. The mixed result is precisely why the study deserves attention without hype. An unexpected therapeutic bridge GLP-1 receptor agonists entered public consciousness as treatments for diabetes and obesity. Yet clinicians and patients began reporting something more difficult

What is the “right” plasma clozapine concentration? A new dose-response meta-analysis in Psychiatry Research offers several provocative numbers. But its most important contribution may be its warning against treating those numbers as universal thresholds. Fornaro and colleagues examined the relationships between plasma clozapine and norclozapine concentrations, therapeutic response and adverse outcomes in people with schizophrenia-spectrum disorders. Their findings reinforce

When should an antipsychotic be judged effective—or ineffective? The usual answer is expressed in weeks. But a new study in The Lancet Psychiatry suggests that the more clinically useful question may be: Which symptoms are we waiting to improve? Leucht and colleagues analyzed individual-participant data from six antipsychotic trials involving 2,079 people with acute schizophrenia. Their findings show that the major symptom domains of schizophrenia improve on meaningfully diff

1. Core Framework: "Getting to Zero" (Barry et al., 2016) The primary thesis established by Barry et al. in Current Epidemiology Reports (2016) is that standard TB control measures (prompt case finding and treatment of active disease) are insufficient for elimination. The Latent TB Infection (LTBI) Reservoir: The vast majority of active TB cases in California (>80%) stem from the reactivation of longstanding, untreated latent TB infections rather than recent transmission with